Literature DB >> 32352607

Adenosine kinase inhibition enhances microvascular dilator function and improves left ventricle diastolic dysfunction.

Alec Davila1, Yanna Tian1, Istvan Czikora1, Amanda S Weissman1, Nicholas Weinand1, Guangkuo Dong2, Jiean Xu3, Jie Li3, Huabo Su3, Gaston Kapuku4, Yuqing Huo3, Zsolt Bagi1.   

Abstract

OBJECTIVE: Inhibition of adenosine kinase (ADK), via augmenting endogenous adenosine levels exerts cardiovascular protection. We tested the hypothesis that ADK inhibition improves microvascular dilator and left ventricle (LV) contractile function under metabolic or hemodynamic stress. METHODS AND
RESULTS: In Obese diabetic Zucker fatty/spontaneously hypertensive heart failure F1 hybrid rats, treatment with the selective ADK inhibitor, ABT-702 (1.5 mg/kg, intraperitoneal injections for 8-week) restored acetylcholine-, sodium nitroprusside-, and adenosine-induced dilations in isolated coronary arterioles, an effect that was accompanied by normalized end-diastolic pressure (in mm Hg, Lean: 3.4 ± 0.6, Obese: 17.6 ± 4.2, Obese + ABT: 6.6 ± 1.4) and LV relaxation constant, Tau (in ms, Lean: 6.9 ± 1.5, Obese: 13.9 ± 1.7, Obese + ABT: 6.0 ± 1.1). Mice with vascular endothelium selective ADK deletion (ADKVEC KO) exhibited an enhanced dilation to acetylcholine in isolated gracilis muscle (lgEC50 WT: -8.2 ± 0.1, ADKVEC KO: -8.8 ± 0.1, P < .05) and mesenteric arterioles (lgEC50 WT: -7.4 ± 0.2, ADKVEC KO: -8.1 ± 1.2, P < .05) when compared to wild-type (WT) mice, whereas relaxation of the femoral artery and aorta (lgEC50 WT: -7.03 ± 0.6, ADKVEC KO: -7.05 ± 0.8) was similar in the two groups. Wild-type mice progressively developed LV systolic and diastolic dysfunction when they underwent transverse aortic constriction surgery, whereas ADKVEC -KO mice displayed a lesser degree in decline of LV function.
CONCLUSIONS: Our results indicate that ADK inhibition selectively enhances microvascular vasodilator function, whereby it improves LV perfusion and LV contractile function under metabolic and hemodynamic stress.
© 2020 John Wiley & Sons Ltd.

Entities:  

Keywords:  adenosine-kinase; coronary microcirculation; heart failure with preserved ejection fraction

Year:  2020        PMID: 32352607      PMCID: PMC7752304          DOI: 10.1111/micc.12624

Source DB:  PubMed          Journal:  Microcirculation        ISSN: 1073-9688            Impact factor:   2.628


  31 in total

1.  Increased cyclooxygenase-2 expression and prostaglandin-mediated dilation in coronary arterioles of patients with diabetes mellitus.

Authors:  Tamás Szerafin; Nóra Erdei; Tibor Fülöp; Eniko T Pasztor; István Edes; Akos Koller; Zsolt Bagi
Journal:  Circ Res       Date:  2006-08-17       Impact factor: 17.367

2.  Endothelial adenosine kinase deficiency ameliorates diet-induced insulin resistance.

Authors:  Jiean Xu; Qiuhua Yang; Xiaoyu Zhang; Zhiping Liu; Yapeng Cao; Lina Wang; Yaqi Zhou; Xianqiu Zeng; Qian Ma; Yiming Xu; Yong Wang; Lei Huang; Zhen Han; Tao Wang; David Stepp; Zsolt Bagi; Chaodong Wu; Mei Hong; Yuqing Huo
Journal:  J Endocrinol       Date:  2019-08       Impact factor: 4.286

Review 3.  Heart failure with preserved ejection fraction: pathophysiology, diagnosis, and treatment.

Authors:  Barry A Borlaug; Walter J Paulus
Journal:  Eur Heart J       Date:  2010-12-07       Impact factor: 29.983

4.  A1 adenosine receptor upregulation accompanies decreasing myocardial adenosine levels in mice with left ventricular dysfunction.

Authors:  Hajime Funakoshi; Lefteris C Zacharia; Zhonghua Tang; Jin Zhang; Ling L Lee; Julie C Good; David E Herrmann; Yoshihiro Higuchi; Walter J Koch; Edwin K Jackson; Tung O Chan; Arthur M Feldman
Journal:  Circulation       Date:  2007-04-16       Impact factor: 29.690

5.  ABT-702 (4-amino-5-(3-bromophenyl)-7-(6-morpholino-pyridin- 3-yl)pyrido[2,3-d]pyrimidine), a novel orally effective adenosine kinase inhibitor with analgesic and anti-inflammatory properties. II. In vivo characterization in the rat.

Authors:  E A Kowaluk; J Mikusa; C T Wismer; C Z Zhu; E Schweitzer; J J Lynch; C H Lee; M Jiang; S S Bhagwat; A Gomtsyan; J McKie; B F Cox; J Polakowski; G Reinhart; M Williams; M F Jarvis
Journal:  J Pharmacol Exp Ther       Date:  2000-12       Impact factor: 4.030

6.  cAMP facilitates EDHF-type relaxations in conduit arteries by enhancing electrotonic conduction via gap junctions.

Authors:  Tudor M Griffith; Andrew T Chaytor; Hannah J Taylor; Beverley D Giddings; David H Edwards
Journal:  Proc Natl Acad Sci U S A       Date:  2002-04-23       Impact factor: 11.205

7.  Ecto-5'-nucleotidase, CD73, is an endothelium-derived hyperpolarizing factor synthase.

Authors:  Masanori Ohta; Kazuyoshi Toyama; David D Gutterman; William B Campbell; Vincent Lemaître; Ryutaro Teraoka; Hiroto Miura
Journal:  Arterioscler Thromb Vasc Biol       Date:  2013-01-03       Impact factor: 8.311

8.  Endothelial function in coronary arterioles from pigs with early-stage coronary disease induced by high-fat, high-cholesterol diet: effect of exercise.

Authors:  Kyle K Henderson; James R Turk; James W E Rush; M Harold Laughlin
Journal:  J Appl Physiol (1985)       Date:  2004-06-18

Review 9.  Coronary microvascular obstruction in acute myocardial infarction.

Authors:  Giampaolo Niccoli; Giancarla Scalone; Amir Lerman; Filippo Crea
Journal:  Eur Heart J       Date:  2015-09-12       Impact factor: 29.983

10.  HIF-1-dependent repression of adenosine kinase attenuates hypoxia-induced vascular leak.

Authors:  Julio C Morote-Garcia; Peter Rosenberger; Johannes Kuhlicke; Holger K Eltzschig
Journal:  Blood       Date:  2008-02-28       Impact factor: 22.113

View more
  2 in total

1.  Pharmacological mechanisms of sodium-glucose co-transporter 2 inhibitors in heart failure with preserved ejection fraction.

Authors:  Bo Liang; Yi Liang; Ning Gu
Journal:  BMC Cardiovasc Disord       Date:  2022-06-10       Impact factor: 2.174

Review 2.  Endothelial Dysfunction in Heart Failure With Preserved Ejection Fraction: What are the Experimental Proofs?

Authors:  Lauriane Cornuault; Paul Rouault; Cécile Duplàa; Thierry Couffinhal; Marie-Ange Renault
Journal:  Front Physiol       Date:  2022-07-08       Impact factor: 4.755

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.